SU 3327

10/19

ALTERNATE NAMES: 5-((5-nitrothiazol-2-yl)thio)-1,3,4-thiadiazol-2-amine; 5-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine; JNK Inhibitor XIII; BDBM29315

CATALOG #:
B2923-5 5 mg
B2923-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: $C_5H_3N_5O_2S_3$

MOLECULAR WEIGHT: 261.3

CAS NUMBER: 40045-50-9

APPEARANCE: Solid

PURITY: 95%

SOLUBILITY:
4 mg/ml in Ethanol
50 mg/ml in DMSO

DESCRIPTION: SU 3327 is a selective inhibitor of c-Jun N-terminal kinase (JNK). It shows an IC_{50} of 0.7 μM in the kinase assay. It Inhibits the protein-protein interaction between JNK and JIP with an IC_{50} of 239 nM. It inhibits TNF-α stimulated phosphorylation of c-Jun in cells with an EC_{50} of 6.23 μM. It restores insulin sensitivity in a mouse model of type-2 diabetes.

STORAGE TEMPERATURE: -20ºC. Store in the dark. Product is light sensitive.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:
De S.K., Stebbins, J.L, Chen, L.H., et al. Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J Med Chem. 52(7):1943-52 (2009).

RELATED PRODUCTS:

EZSolution™ SP600125 (Cat. No. 9541)
SP600125 (Cat. No. 1669)
JNK-IN-8 (Cat. No. 2729)
TCS JNK 5a (Cat. No. B1688)
JNK-IN-7 (Cat. No. B1695)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***